DermTech, Inc.

DermTech, Inc. (Nasdaq: DMTK) is a molecular diagnostics company focused on non-invasive genomic testing for dermatological conditions, including its Pigmented Lesion Assay for melanoma detection. The La Jolla, California-based company initially pursued a traditional public offering, filing an S-1/A amendment with the SEC on June 9, 2017, before ultimately accessing public markets through a SPAC merger with Constellation Alpha Capital Corp. in August 2019. Constellation Alpha Capital had completed its own IPO in 2017, with the combined company subsequently trading on Nasdaq under the DMTK ticker. DermTech operates in the clinical diagnostics and precision medicine sector, targeting the dermatology specialty market. Visit SpacDesk and sign up for full data on DMTK, including filing history, transaction terms, and post-merger performance analytics.